COVID-19 Therapies

25/02/2022

Clinical guide - Therapies for patients hospitalised due to COVID-19 Feb 22

25/02/2022

PHL Antivirals and neutralising monoclonal antibodies (nMABs) covid hosp patients Feb 22

25/02/2022

Interim CCP - antivirals or neutralising Mabs hosp-onset covid (V6) Feb 22

25/02/2022

UK Interim Clinical Commissioning Policy Therapies for patients with symptomatic hosp covid Feb 22

25/02/2022

Interim Clinical Commissioning Policy Remdesivir for patients hospitalised due to COVID-19 (adults and adolescents 12 years and .pdf

25/02/2022

Pharmaceutical Public Link - Remdesivir 25 February 2022

01/02/2022

Interim Clinical Commissioning Policy - IL-6 Inhibitors - 1 Feb.pdf

01/02/2022

Pharmaceutical Public Link - IL-6 Inhibitors - 1 Feb.pdf

31/01/2022

Rapid Policy Statement - Palivizumab - 31 Jan.pdf

31/01/2022

Public Health Link - Palivizumab - 31 Jan.pdf

31/01/2022

Interim Clinical Commissioning Policy - Clinical Guide - nMAbs in hospitalised patients - 31 Jan.pdf

31/01/2022

Interim Clinical Commissioning Policy - nMAbs in hospitalised patients - 31 Jan.pdf

31/01/2022

Public Health Link - nMAbs in hospitalised patients - 31 Jan.pdf

31/01/2022

Interim Clinical Commissioning Policy - nMAbs in non-hospitalised patients - 31 Jan.pdf

31/01/2022

Interim Clinical Commissioning Policy - Clinical Guide - nMAbs in non-hospitalised patients - 31 Jan.pdf

31/01/2022

Public Health Link - nMAbs in non-hospitalised patients - 31 Jan.pdf

06/01/2022

Public Health Link - nMAbs in non-hospitalised patients - 4 Jan.pdf

06/01/2022

Interim Clinical Commissioning Policy - nMAbs in non-hospitalised patients - 4 Jan.pdf

06/01/2022

Public Health Link - nMAbs in hospitalised patients - 4 Jan.pdf

06/01/2022

Interim Clinical Commissioning Policy - nMAbs in hospitalised patients - 4 Jan.pdf